II

ImageneBio Inc

IMA·NASDAQ

$5.69

+2.3%
HealthcareBiotechnology

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

At a Glance

Live Snapshot
Market Cap$64.18M
EPS-10.7600
P/E Ratio-0.53
Earnings Date07/23/2026

ima

Research Development Expenses

Last Annual Value

28.52M

3-Year CAGR

-24%

5-Year CAGR

-9%

10-Year CAGR

-3%

II

ImageneBio Inc Competitors Analysis of research-development-expenses

IMA · NASDAQ
Companyresearch-development-expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
IMA logo
ImageneBio Inc
NASDAQ:IMA
28.52M
-21.8%-9.5%N/A 
18.59M
25.3%-21.1%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
99.13M
-2.2%15.2%32.5%
4.94M
-29.5%20.2%32.2%
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
81.98M
-0.5%6.1%10.6%
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
3.12M
16.7%50.0%N/A
9.12M
-10.9%8.4%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
201.58M
43.6%32.8%21.7%
166.42M
-2.7%9.8%14.3%
25.58M
-3.6%-11.4%10.3%
30.75M
38.0%-23.8%N/A
II

ImageneBio Inc Fair Value Envelope

IMA · NASDAQ

Our analysis suggests that IMA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.69, this represents a potential HIDDEN relative to our calculated worth for ImageneBio Inc.

Intrinsic Value
Current Price: $5.69